
VSAR
Other · Other · $43.1M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2018
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 3 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 7, 2018 | Time not confirmed | -0.96 | -0.27 | +71.9% |
| May 8, 2018 | Time not confirmed | -0.86 | -0.25 | +70.9% |
| Mar 1, 2018 | Time not confirmed | -0.93 | 0.87 | +193.5% |
Versartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. It is developing somavaratan, a long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. The company was founded in 2008 and is headquartered in Menlo Park, California.